Foley Hoag Advises Orig3n in Closing of Series B Funding Round

August 28, 2018

Foley Hoag LLP recently advised biotech research company Orig3n in closing its Series B round led by Haitong International. The round brings Orig3n’s total funding to over $50 million since its founding in 2014. Orig3n will use the funds for international and domestic expansion of its direct to consumer genetic testing business, and advancement of its cell therapy programs in osteoarthritis and cardiology.

Boston-based Orig3n offers lifestyle-focused genetic tests to help consumers make educated choices regarding nutrition, fitness, behavior, skincare and more. The company also manages the world’s largest human cell bank dedicated to the commercialization of regenerative medicine therapies. 

Foley Hoag attorneys Colin Zick, Amanda Vendig and Mark Potash advised Orig3n in the transaction.

 

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.